Table 1.

List of US Food and Drug Administration (FDA)–Approved Nanomedicines for Cancer Treatment.

Trade name	Description of carrier	Nanoparticle advantage	Indication(s)	Year(s) approved	Ref
Doxil	Liposomal doxorubicin	Decrease in systemic toxicity of free drug and improved delivery to site of disease	Karposi sarcoma; ovarian cancer; multiple myeloma	1995	45
DaunoXome	Liposomal daunorubicin	Lower systemic toxicity arising from side effects and increased delivery to tumor site	Karposi sarcoma	1996	46
Myocet	Liposomal doxorubicin	Decrease in systemic toxicity of free drug and improved delivery to site of disease	Metastatic breast cancer	2005	47
Onivyde	Liposomal Irinotecan	Lower systemic toxicity arising from side effects and increased delivery to tumor site	Pancreatic cancer	2015	48
DepoCyt	Liposomal cytarabine	Lower systemic toxicity arising from side effects and increased delivery to tumor site	Lymphomatous meningitis	1996	49
Marqibo	Liposomal Vincristine	Lower systemic toxicity arising from side effects and increased delivery to tumor site	Acute lymphoblastic leukemia	2012	50
Abraxane	Albumin-bound paclitaxel nanoparticles	Improved solubility; improved delivery to tumor	Breast cancer; non-small cell lung cancer; pancreatic cancer	2005	51
Eligard	Leuprolide acetate and polymer; PLGH (poly (DL-Lactide-co-glycolide)	Controlled delivery of payload with longer circulation time	Prostate cancer	2002	52